MarketPeel
Insider Trading Intelligence
DL

Deerfield Partners, L.p.

NUVL
DIRECTOR · NUVALENT, INC. · CIK 0001301041
FILING MIX · LIFETIME62%/38%
BUYS
38
SELLS
23
TOTAL VALUE
$371.71M
COMPANIES
14
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
34,631,403
AVG SELL PX
$79.59
TRADE KIND
SHOWING 61 / 61
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
28 backtested trades · 8 horizons · 22 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Deerfield Partners, L.p., measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d28+60.71%-0.88%+0.42%-1.30%-2.12%
14d28+35.71%+1.61%+0.24%+1.36%-5.80%
30d28+53.57%-7.23%-0.94%-6.29%-8.69%
60d28+39.29%-9.26%+0.69%-9.94%-12.39%
90d28+35.71%-4.91%+3.29%-3.24%-3.20%
180d28(4 pending)+41.67%-3.21%+5.74%-8.76%-4.85%
1y28(8 pending)+55.00%-7.60%+14.63%-22.23%-24.05%
2y28(10 pending)+38.89%-29.85%+28.36%-58.20%-63.52%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
NUVL · 8,299,225 shares · as of Nov 24, 2025
02,167,6284,335,2566,502,8848,670,512202320242025SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 38 buys / 23 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
831,978$5.00$4.16M8,153,107Feb 27, 2026Mar 2, 2026View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
2,000,000$5.00$10.00M6,207,982Feb 27, 2026Mar 2, 2026View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
1,084,012$5.00$5.42M10,622,957Feb 27, 2026Mar 2, 2026View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
1,084,010$5.00$5.42M10,622,928Feb 27, 2026Mar 2, 2026View →
NUVL
NUVALENT, INC.
SALE
371,287$95.45$35.44M8,299,225Nov 24, 2025Nov 24, 2025View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
3,387,539$3.20$10.84M9,538,945Jul 31, 2025Aug 4, 2025View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
2,599,932$3.20$8.32M7,321,129Jul 31, 2025Aug 4, 2025View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
3,387,529$3.20$10.84M9,538,918Jul 31, 2025Aug 4, 2025View →
NUVL
NUVALENT, INC.
SALE
1,000,000$97.75$97.75M8,670,512Oct 22, 2024Oct 24, 2024View →
BCAX
BICARA THERAPEUTICS INC.
SALE
7,973,3250Sep 17, 2024Sep 17, 2024View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
35,000$18.00$630.0K897,587Sep 17, 2024Sep 17, 2024View →
BCAX
BICARA THERAPEUTICS INC.
PURCHASE
862,587862,587Sep 17, 2024Sep 17, 2024View →
AHCO
ADAPTHEALTH CORP.
SALE
114,906$10.70$1.23M11,528,863Mar 12, 2024Mar 12, 2024View →
AHCO
ADAPTHEALTH CORP.
SALE
94,567$10.92$1.03M11,731,809Mar 11, 2024Mar 12, 2024View →
AHCO
ADAPTHEALTH CORP.
SALE
88,040$11.13$979.9K11,643,769Mar 11, 2024Mar 12, 2024View →
AHCO
ADAPTHEALTH CORP.
SALE
47,992$10.92$524.1K11,830,871Mar 8, 2024Mar 12, 2024View →
AHCO
ADAPTHEALTH CORP.
SALE
4,495$11.03$49.6K11,826,376Mar 8, 2024Mar 12, 2024View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
1,430,206$8.74$12.50M6,151,406Feb 16, 2024Feb 16, 2024View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
1,430,206$8.74$12.50M6,151,389Feb 16, 2024Feb 16, 2024View →
LRMR
LARIMAR THERAPEUTICS, INC.
PURCHASE
1,430,205$8.74$12.50M4,207,982Feb 16, 2024Feb 16, 2024View →
NUVL
NUVALENT, INC.
PURCHASE
650,000$33.50$21.77M650,000Nov 3, 2022Nov 7, 2022View →
PEPG
PEPGEN INC.
PURCHASE
268,480268,480May 10, 2022May 10, 2022View →
PEPG
PEPGEN INC.
SALE
273,3130May 10, 2022May 10, 2022View →
PEPG
PEPGEN INC.
PURCHASE
208,333$12.00$2.50M476,813May 10, 2022May 10, 2022View →
TOI
ONCOLOGY INSTITUTE, INC.
SALE
85,1130Nov 12, 2021Nov 16, 2021View →
TOI
ONCOLOGY INSTITUTE, INC.
SALE
400Nov 12, 2021Nov 16, 2021View →
TOI
ONCOLOGY INSTITUTE, INC.
PURCHASE
85,11385,113Nov 12, 2021Nov 16, 2021View →
TOI
ONCOLOGY INSTITUTE, INC.
SALE
14,88785,113Nov 12, 2021Nov 16, 2021View →
TOI
ONCOLOGY INSTITUTE, INC.
PURCHASE
4040Nov 12, 2021Nov 16, 2021View →
TOI
ONCOLOGY INSTITUTE, INC.
PURCHASE
50,000$1,000.00$50.00M58,945Nov 12, 2021Nov 16, 2021View →
TOI
ONCOLOGY INSTITUTE, INC.
PURCHASE
625,000625,000Nov 12, 2021Nov 16, 2021View →
TOI
ONCOLOGY INSTITUTE, INC.
PURCHASE
3,177,5433,177,543Nov 12, 2021Nov 16, 2021View →
TOI
ONCOLOGY INSTITUTE, INC.
SALE
707,96040Nov 12, 2021Nov 16, 2021View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASE
756,472756,472Oct 26, 2021Oct 28, 2021View →
XLO
XILIO THERAPEUTICS, INC.
PURCHASE
387,500$16.00$6.20M1,143,972Oct 26, 2021Oct 28, 2021View →
XLO
XILIO THERAPEUTICS, INC.
SALE
7,186,4890Oct 26, 2021Oct 28, 2021View →
HOWL
WEREWOLF THERAPEUTICS, INC.
PURCHASE
1,752,7871,752,787May 4, 2021May 4, 2021View →
HOWL
WEREWOLF THERAPEUTICS, INC.
PURCHASE
800,000$16.00$12.80M2,552,787May 4, 2021May 4, 2021View →
HOWL
WEREWOLF THERAPEUTICS, INC.
SALE
15,195,0940May 4, 2021May 4, 2021View →
TERN
TERNS PHARMACEUTICALS, INC.
PURCHASE
1,717,0331,717,033Feb 9, 2021Feb 9, 2021View →
TERN
TERNS PHARMACEUTICALS, INC.
SALE
1,717,0330Feb 9, 2021Feb 9, 2021View →
TERN
TERNS PHARMACEUTICALS, INC.
PURCHASE
665,000$17.00$11.30M2,382,033Feb 9, 2021Feb 9, 2021View →
ANNX
ANNEXON, INC.
SALE
4,043,0320Jul 28, 2020Jul 28, 2020View →
ANNX
ANNEXON, INC.
SALE
4,043,0310Jul 28, 2020Jul 28, 2020View →
ANNX
ANNEXON, INC.
PURCHASE
350,000$17.00$5.95M808,914Jul 28, 2020Jul 28, 2020View →
ANNX
ANNEXON, INC.
PURCHASE
458,914458,914Jul 28, 2020Jul 28, 2020View →
NKTX
NKARTA, INC.
PURCHASE
500,000$18.00$9.00M1,209,936Jul 14, 2020Jul 14, 2020View →
NKTX
NKARTA, INC.
PURCHASE
709,936709,936Jul 14, 2020Jul 14, 2020View →
NKTX
NKARTA, INC.
SALE
2,626,7670Jul 14, 2020Jul 14, 2020View →
RVMD
REVOLUTION MEDICINES, INC.
PURCHASE
997,589997,589Feb 18, 2020Feb 18, 2020View →
RVMD
REVOLUTION MEDICINES, INC.
PURCHASE
498,795498,795Feb 18, 2020Feb 18, 2020View →
RVMD
REVOLUTION MEDICINES, INC.
PURCHASE
300,000$17.00$5.10M798,795Feb 18, 2020Feb 18, 2020View →
RVMD
REVOLUTION MEDICINES, INC.
SALE
997,5890Feb 18, 2020Feb 18, 2020View →
RVMD
REVOLUTION MEDICINES, INC.
PURCHASE
300,000$17.00$5.10M1,297,589Feb 18, 2020Feb 18, 2020View →
RVMD
REVOLUTION MEDICINES, INC.
SALE
498,7950Feb 18, 2020Feb 18, 2020View →
SDGR
SCHRODINGER, INC.
PURCHASE
250,000$17.00$4.25M250,000Feb 10, 2020Feb 10, 2020View →
SDGR
SCHRODINGER, INC.
PURCHASE
1,346,1671,346,167Feb 10, 2020Feb 10, 2020View →
SDGR
SCHRODINGER, INC.
SALE
10,063,0610Feb 10, 2020Feb 10, 2020View →
BDTX
BLACK DIAMOND THERAPEUTICS, INC.
PURCHASE
400,000$19.00$7.60M778,790Feb 3, 2020Feb 3, 2020View →
BDTX
BLACK DIAMOND THERAPEUTICS, INC.
PURCHASE
378,790378,790Feb 3, 2020Feb 3, 2020View →
BDTX
BLACK DIAMOND THERAPEUTICS, INC.
SALE
1,142,3610Feb 3, 2020Feb 3, 2020View →
Other insiders · NUVL
Loading peer insiders…
About this filer
CIK 0001301041
ROLE
Director
PRIMARY
NUVL
COMPANIES
14
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001301041DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback